Ophthalmic solution containing poly-1,3-beta-glucoside



United States Patent ICC 3,415,929

Patented Dec. 10, 1968 1 2 i and the like, an antibiotic, such as neomycin, gramicidin, 3,415,929 polymlxm, bacitracin and the like, or a chemotherapeutic agent, such as neostigmine, piperocaine, chlorphenira- Leon Lachman, Minbum and Pravin Shem summit, nnne, phenyl ephrine, tetracaine, sulfacetamide, sulfisox- NJ assignors to cum Corporation, New Yiuk, N'Yv 5 azole, idoxu ndme, tetrahydrozoline, naphazoline, antazoa corporation f Delaware line, echothiophate and the like, advantageously in the No Drawing. Filed July 14, 1965, Ser. No. 472,012 form of a water-soluble salt or another useful derivative 11 Claims. (Cl. 424-229) thereof.

Specifically mentioned are atropine sulfate, homatro- The present invention concerns and has for its object pine bromide, scopolamine bromide, physostigmine sathe provision of an ophthalmic solution vehicle providing licylate, pilocarpine chloride, l-epinephrine bitartrate,

a prolonged duration of drug activity. rednisolone ZI-acetate or trimethy'lacetate, dexametha- Ophthalmic solutions usually are short acting. In certain sone ZI-phosphate, triamcinolone acetonide, neornycin instances, such as glaucoma patients, the eye has to be sulfate, polymixin B sulfate, neostigmine maleate, pheny1- medicated for long periods at prescribed intervals, for 15 ephrine chlorine, tetracaine chloride, sodium sulfacetamexample, every 3 to 4 hours. In order to maintain the ide, diethanolammonium sulfisoxazole, tetrahydrozoline intraocular tension in these patients at a comfortable level, chloride, naphazoline chloride, antazoline phosphate and it would be considerably more convenient, if they had echothiophate iodide. only to instill drops into their eyes once or twice a day, Especially useful are compositions containing as the e.g. in the morning and evening, rather than four times active ingredient physostigmine salicylate, homatropine during the day. hydrochloride or bromide, tropic acid amide and pilo- Therefore, considerable efforts have been spent to decarpine hydrochloride together with an aqueous vehicle velop a vehicle for ophthalmic solutions which would containing said poly-1,3-B-glucoside. cause the drug to exhibit a prolonged duration of thera- The composition of the invention contain these medicapeutic action. One of the outcoming results were, for ments in the known and useful concentration besides the example, the present use of methylcellulose, carboXypoly-l-3,- 8-glucoside, of which in most instances a content methylcellulose, hydroxypropylmethylcellulose or polyof about 0.5% is sufficient for the maximal effect. sorbatc for this purpose. The ophthalmic solutions according to the invention We have now found that the linear poly 1-3,-}8-glucoare generally prepared according to methods used in the side, containing on every third glucose moiety of he Cha n art of manufacturing ophthalmic preparations, essentially a 1,6-[3-glucosido group, is highly efficient for the above by combining the specified proportions of the active inoutlined purpose, since it is non-toxic, non-irritating to rcdients as well as the poly-1,3-fi-glucoside with pharmathe eye and yet when added in low C HCGH Yafi II 110 n ceutically acceptable aqueous carrier solutions. These are ophthalmic solution causes the drug to exhibit a prolonged ith purified at alone i t of water d effect when tested, for example, in the rabbits eye, as water-miscible solvents, such as lower alkanols or aralkacompared to the same solution without said additive. nols, e g., ethanol or benzyl alcohol, lower alkylene Accordingly, the Pmsallt invenllon concerns glycols or polygilycols, e.g. ethylene glycol, propylene glycol, polyvinyl alcohol or polyethyleneglycol. Other ingredients that may be added to ensure stable solutions are, for example, stabilizers, such as thiourea, isoascor-bic acid, creatinine, sodium thiosulfate, bisulfite or metabisulfite, monothioglycerol or thiosorbitol, any known chelating agents, such as ethylenediamine tetraacetic acid and its monoor polysalts, sodium citrate or gluconate, buffers or buffer combinations, such as acetic acid, sodium acetate or sodium dihydrogenphosphate-disodium hydrogenphos- The poly-1,3- 3-glucoside used according to the invenphate, salts for making isotonic solutions, such as sodium tion mainly has the following formula: chloride, preserving agents, such as sodium borate,

' 2 a ca 0a ca OH 0 2 o a o o o a H on a Ho H A preferred form there is that of which a 1% aqueous phenylmercuric nitrate, benzalkonium chloride, thimerosolution shows at 24 C. and in the pH-range between sal, methyl or propyl paraben and the like.

6.8 and 7.5 a final viscosity (after 5 hours) of about 60 The following working examples are illustrative of the 2400 to 3000 centipoises, measured with a Brookfield invention, but are in no way intended to limit its scope.

viscosimeter using a No. 3 spindle. Temperatures are given in degrees Centigrade and all This poly-1,3-fl-glucoside is used in the ophthalmic parts are parts by weight.

vehicle of the present invention in an amount ranging (a) an aqueous ophthalmic vehicle containing an effective amount of said poly-1,3-B-glucoside. 40

(b) an ophthalmic composition comprising a therapeutically acceptable, water soluble form of an eye medicament together 'with the vehicle mentioned under (a), and

(c) the use of said poly-1,3-fi-glusoside in the preparation of ophthalmic compositions.

between about 0.05 and 5%, preferably between about EXAMPLE 1 0.1 and 2% and advantageously between about 0.1 and Formula The eye medicament useful in the compositions of Percent the invention may be an alkaloid, such as atropine, Prednisolone 21-actate 0.5 homatropine, scopolamine, physostigmine, pilocarpine 7O Thimerosal 0.001 and the like, a hormone, such as epinephrine, hydro- Poly-1,3-fi-glucoside 0.5

cortisone, rednisolone, dexamethasone, triamcinolone Water for injection Q.s.

PROCEDURE Dissolve the polyglucoside in 50% of the water for injection heated to 90 C. with constant stirring. Cool the solution to 40 C. and dissolve the thimerosal and prednisolone 21-acetate. Cool the solution to room temperature and bring up to volume with water for injection. Pass the solution through a suitable filter and fill into appropriate containers. Sterilize by autoclaving at 121 for 20 minutes.

EXAMPLE 2 Formula Percent Pilocarpine hydrochloride 0. Thimerosal 0. 002

Poly-1,3-fi-glucoside 0. 75 Water for injection Q.s. Sodium chloride Q.s.

1 To adjust isotonicity.

PROCEDURE EXAMPLE 3 Formula Percent Homatropine hydrochloride 5 Chlorobutanol 0.5 Poly-1,3-fl-glucoside 0.75 Water for injection 1 Q.s. Sodium chloride Q.s.

1 To adjust isotonicity.

PROCEDURE Dissolve the polyglucoside in 50% of the water for injection heated to 90 C. with constant stirring. Cool the solution to 40 C. and dissolve the chlorobutanol and homatropine hydrochloride and the required amount of sodium chloride to adjust the isotonicity of the solution Cool the solution to room temperature and bring up to volume with water for injection. Pass the solution through a suitable filter and fill into appropriate containers. Sterilize by autoclaving at 121 for 20 minutes.

EXAMPLE 4 Formula Percent Tropic acid amide 0.5 Phenylmercuric acetate 0.002 Po1y-1,3-/8-glucoside 0.75 Water for injection Q.s.

PROCEDURE Dissolve the polyglucoside in 50% of the water for injection heated to 90 C. with constant stirring. Cool the solution to 40 C. and dissolve the phenylmercuric acetate and tropic acid amide. Cool the solution to room temperature and bring up to volume with water for injection. Pass the solution through a suitable filter and fill into appropriate containers. Sterilize by autoclaving at 121 for 20 minutes.

EXAMPLE 5 Formula Percent Physostigmine salicylate 0.5 Chlorobutanol 0. Soodium thiosulfate 0.3 Poly-1,3-B-glucoside 1.0 Water for injection Q.s.

PROCEDURE Dissolve the polyglucoside in 50% of the Water for injection heated to C. with constant stirring. Cool the solution to 40 C. and dissolve the sodium thiosulfate, chlorobutanol and physostigmine salicylate. Cool the solution to room temperature and bring up to volume with water for injection. Pass the solution through a suitable filter and fill into appropriate containers. Sterilize by autoclaving at 121 for 20 minutes.

EXAMPLE 6 Formula Percent Sodium sulfacetamide 15 Poly-1,3-B-glucoside 0.5 Chlorobutanol 0.15 Water for injection Q.s.

PROCEDURE Dissolve the polyglucoside in 50% of the Water for injection heated to 90 C. with constant stirring. Cool the solution to 40 C. and dissolve the chlorobutanol and sodium sulfacetamide. Cool to room temperature and bring up to volume with water for injection. Pass the solution through a suitable filter and fill into appropriate containers. Sterilize by autoclaving at 121 for 20 minutes.

EXAMPLE 7 Formula Percent Sulfamethizole 15 Poly-1,3-fl-glucoside 0.75 Water for injection Q.s.

PROCEDURE Dissolve the polyglucoside in 50% of the water for injection heated to 90 with constant stirring. Cool the solution to 40 C. and dissolve the sul-famethizole. Cool the solution to room temperature and bring up to volume with Water for injection. Pass the solution through a suitable filter and fill into appropriate containers. Sterilize by autoclaving at 121 for 20 minutes.

What is claimed is:

1. A solution comprising (a) about 0.05 to 5% of the linear poly-1,3-[3-glucoside, containing on every third glucose moiety of the chain a 1,6- 8-glucosido group and of which an 1% aqueous solution shows at 24 C. and in the pH range between 6.8 and 7.5 a final viscosity of about 2400 to 3000 centipoises, and (b) a pharmaceutically acceptable aqueous ophthalmic carrier solution.

2. A solution is claimed in claim 1, wherein the content of the poly-1,3-fi-glucoside ranges between about 0.1 and 2%.

3. A solution as claimed in claim 1, Whrein the content of the poly-1,3-fl-glucoside ranges between about 0.1 and 1%.

4. A solution as claimed in claim 1, together with a therapeutically efiective amount of a member selected from the group consisting of atropine sulfate, homatropine bromide, scopolamine bromide, physostigmine salicylate, pilocarpine chloride, l-epinephrine bitartrate, prednisolone 21-acetate, prednisolone 2l-trimethylacetate, dexamethasone 21-phosphate, triamcinolone acetonide, neomycine sulfate, polymixin B sulfate, neostigmine bromide, neostigmine methylsul-fate, piperocaine chloride, chlorphemiramine maleate, phenylephrine chloride, tetra caine chloride, sodium sulfacetamide, diethanolammonium sulfisoxazole, tetrahydrozoline chloride, naphthazoline chloride, antazoline phosphate and echothiophate iodide.

5. A solution as claimed in claim 3, together with a therapeutically effective amount of physostigmine salicylate.

6. A solution as claimed in claim 3, together with a therapeutically effective amount of a member selected from the group consisting of homatropine hydrochloride therapeutically effective amount of sodium sulfacetamide. and homatropine hydro-bromide. 11. A solution as claimed in claim 3, together with a 7. A solution as claimed in claim 3, together with a therapeutically eflective amount of sulfamethizole. therapeutically effective amount of tropic acid amide.

8. A solution as claimed in claim 3 together with a 5 References Cited zlllggaipggtically elfectlve amount of pllocarpme hydro- FOREIGN PATENTS 9. A solution as claimed in claim 3, together with a 639,361 4/1964 Belgiumglzrgfeeutically effective amount of prednisolone 21- ALBERT T- MEYERS, Primary Examiner.

10. A solution as claimed in claim 3, together with a D. A. MAHANAND, Assistant Examiner. 

1. A SOLUTION COMPRISING (A) ABOUT 0.05 TO 5% OF THE LINEAR POLY-1,3-B-GLUCOSIDE, CONTAINING ON EVERY THIRD GLUCOSE MOIETY OF THE CHAIN A 1,6-B-GLUCOSIDO GROUP AND OF WHICH AN 1% AQUEOUS SOLUTION SHOWS AT 24*C. AND IN THE PH RANGE BETWEEN 6.8 AND 7.5 A FINAL VISCOSITY OF ABOUT 2400 TO 3000 CENTIPOISES, AND (B) A PHARMACEUTICALLY ACCEPTABLE AQUEOUS OPHTHALMIC CARRIER SOLUTION. 